
Billions on the table, GSK’s Hal Barron antes $120M cash to partner with a specialist in synthetic lethality
GSK R&D chief Hal Barron has turned to another Bay Area biotech for his latest oncology drug development pact, which could total billions for a preclinical deal that starts with $120 million in cash. And this one speaks directly to one of his favorite topics: synthetic lethality.
Barron is partnering with Ideaya Biosciences $IDYA for this new alliance. GSK is handing over $100 million in upfront cash, plus another $20 million for a chunk of stock.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.